The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges.
Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY. · 2019
Read The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. by Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6830116.txt.
Introduction
Loh and co-authors review a key switch in cancer spread, in the journal Cells. Many tumours begin in epithelial tissue, whose cells sit in ordered sheets. To spread, they loosen and turn mobile, a change called epithelial-to-mesenchymal transition. Its hallmark is a swap of grip proteins. Cells lose E-cadherin and gain N-cadherin.
The review explains what each cadherin does in healthy tissue and in tumours. It traces the signals and master genes that flip the switch. Those include well-known pathways such as Wnt and Hippo. The swap also feeds drug resistance and stem-like traits. The authors discuss natural compounds and other ways to block the change.
Catalog record
| CREATOR | Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 126 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges By Chin-Yap Loh, Jian Yi Chai, Ting Fang Tang, Won Fen Wong, Gautam Sethi, Muthu Kumaraswamy Shanmugam, Pei Pei Chong, Chung Yeng Looi Published in: Cells DOI: 10.3390/cells8101118 ABSTRACT Epithelial-to-Mesenchymal Transition (EMT) has been shown to be crucial in tumorigenesis where the EMT program enhances metastasis, chemoresistance and tumor stemness. Due to its emerging role as a pivotal driver of tumorigenesis, targeting EMT is of great therapeutic interest in counteracting metastasis and chemoresistance in cancer patients. The hallmark of EMT is the upregulation of N-cadherin followed by the downregulation of E-cadherin, and this process is regulated by a complex network of signaling pathways and transcription factors. In this review, we summarized the recent understanding of the roles of E- and N-cadherins in cancer invasion and metastasis as well as the crosstalk with other signaling pathways involved in EMT. We also highlighted a few natural compounds with potential anti-EMT property and outlined the future directions in the development of novel intervention in human cancer treatments. We have reviewed 287 published papers related to this topic and identified some of the challenges faced in translating the discovery work from bench to bedside. 1. INTRODUCTION Cadherins were originally identified by Takeichi as cell surface molecules involved in Ca2+-dependent adhesion mechanism in Chinese hamster V79 cells [1]. Cadherins are highly sensitive to Ca2+ and are readily degraded by proteolysis in the absence of Ca2+ [2]. The cadherin superfamily consists of 114 calcium-dependent membrane proteins from three major cadherin families (cadherins, protocadherins and cadherin-related proteins), and these proteins from different families differ in many aspects from each other [3,4]. Different cadherins share similar overall primary structures, with their mature forms consisting of 723 to 748 amino acids [2]. Cadherins are involved in regulating cell–cell adhesion as well as modulating crucial morphogenetic and differentiation processes during development [5,6]. The classical cadherins are single span transmembrane cadherins with five extracellular cadherin (EC) repeat domains that cooperate with catenin family members via their cytoplasmic domains to link with the underlying actin cytoskeleton [7,8]. Classical cadherins are grouped into type-I and type-II subgroups based on the molecular features of their interaction via the cadherin motif [7]. Classical cadherins mediate segregation of different cell populations based on homophilic adhesion mechanism where the cells expressing different cadherin subtypes keep apart from each other [9]. A “strand-dimer” model has been widely accepted for the homophilic adhesion mechanism of type I cadherins [10]. This model is a trans interaction involving six highly conserved N-terminal residues of EC1 known as “adhesion arm” and the conserved “acceptor pocket” in the body of EC1, in which the adhesion arm from one cadherin inserts into acceptor pocket of the opposing cadherin [10]. E- and N-cadherin belong to type-I classical cadherins alongside P-cadherin, R-cadherin and M-cadherin. The size of mature E-cadherin protein is 120 kDa while mature N-cadherin protein is 130 kDa. Structure of E- and N-cadherin are as illustrated in Figure 1. Cadherin cytoplasmic tails attach with β-catenin which connects to α-catenin, thus form the cadherin-catenin adhesion complex [11]. Although α-catenin and β-catenin are crucial in the binding of cadherin to F-actin, they cannot bind F-actin directly; hence, additional adaptors such as vinculin, eplin or zona occludens protein 1 (ZO1) are required (Figure 1) [12]. Interestingly, in comparison with the E-cadherin adhesions, the wild-type vinculin is highly extended in N-cadherin adhesions [13]. The expression of α-catenin determines the z-positioning of vinculin and emplaces vinculin in the interface zone, allowing it to bridge the cadherin-catenin and actin compartments [13]. This concurrently regulates the position of zyxin and vasodilator-stimulated phosphoprotein (VASP), which in turn regulates actin [13]. Indeed, a recent study demonstrated that the force-dependent vinculin/α-catenin association is vitally important in the formation of adaptive cell–cell contacts in response to mechanical stress, long-range cell–cell interactions and tissue-scale mechanics [11]. Previous studies showed that the anchoring of cadherin complexes to F-actin mediated by vinculin can restore E-cadherin-dependent cell contacts without the presence of α-catenin actin binding domain [14]. The cadherin–catenin adhesion is the essential component of adherens junctions that maintain tissue stability and dynamic cell movements [11]. Adherens junctions are regulated at the levels of transcription, translation, and trafficking, as well as via post-translational regulation of cadhesome proteins including serine or threonine phosphorylation, tyrosine phosphorylation, and proteolysis [12]. Tension also plays a critical role in the maturation process of cadherin-mediated adhesions. E-cadherin is one of the well-studied founding member of the superfamily and a potent tumor suppressor because downregulation of E-cadherin is often found in malignant epithelial cancers [15,16,17]. E-cadherin is important in maintaining the epithelial phenotype and regulating homeostasis of tissues by modulating various signaling pathways [18]. Mutations, proteolytic cleavage, chromosomal deletions, epigenetic regulation and transcriptional silencing of CDH1 promoter were shown to impede the functionality of E-cadherin in the development of several malignancies including gastric, breast, liver, pancreas, and skin [19,20,21,22,23]. Loss of E-cadherin in cancer cells leads to metastatic dissemination and activation of several EMT transcription factors [24]. Ovarian cancer cell lines with higher E-cadherin expression showed poorer resistance to cell death, lower adhesion to extracellular matrices and weaker invasiveness in comparison to cell lines with higher N-cadherin expression [17]. E-cadherin is proven to promote nucleotide excision repair by increasing the expression of xeroderma pigmentosum complementation group C (XPC) and DNA damage-binding protein 1 (DDB1) in the event of ultraviolet-induced DNA damage [25]. Uncontrolled growth due to dysfunctional contact inhibition of proliferation is one of the specific features of solid cancers [26,27]. Homophilic binding of E-cadherin inhibits cell proliferation by regulating expression levels of receptor tyrosine kinase (RTK) and tyrosine kinase Src in the absence of cell–cell interaction [28]. E-cadherin-expressing cell line with elevated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activity and upregulated c-Myc expression was demonstrated to promote cell proliferation following the increase in adenosine triphosphate (ATP) production by glycolysis and mitochondrial oxidative phosphorylation (OXPHOS) [29]. Cancer cells commonly use aerobic glycolysis or mitochondrial OXPHOS, depending on the circumstances, to acquire ATP as energy to sustain their high rates of proliferation [30,31,32]. Most studies suggested that decrease of E-cadherin expression is the hallmark of EMT, but some researchers argued that the loss of E-cadherin is not causal nor a necessity for EMT and restoration of E-cadherin expression in E-cadherin negative malignant cells did not reverse the EMT [33]. Nilsson et al. also demonstrated that E-cadherin loss is consequential rather than causal for c-erbB2-induced EMT in non-malignant mammary epithelial cell line HB2 [34]. Loss of E-cadherin alone has been proved to be insufficient to drive EMT program in non-malignant breast cell line MCF10A [35]. However, the loss of E-cadherin expression has always been associated with more aggressive and less differentiated malignant cells. Besides, the loss of E-cadherin has been reported to cause activation of several EMT transcription factors, as aforementioned. Therefore, the loss of E-cadherin is a major driver or consequence of EMT remains a question to be answered. Various invasive and metastatic cancers have been associated with high level of E-cadherin expression, notably in patients with prostate cancer [36], ovarian cancer [37], and glioblastoma [38], thus suggesting that E-cadherin promotes metastasis in certain tumors instead of suppressing tumor progression. Dual roles